The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma: A phase II randomized trial of the Italian Oncology Group for Clinical Research

Cancer

Volumn 77, Issue 2, 1996, Pages 245-250

  De Lisi, Vincenzo ^{a,b,c,d,e,f,g,h}   Cocconi, Giorgio ^{a,b,c,d,e,f,g}   Angelini, Francesco ^{a,b,c,d,e,f,g}   Cavicchi, Francesco ^{a,b,c,d,e,f,g}   Di Costanzo, Francesco ^{a,b,c,d,e,f,g}   Gilli, Germana ^{a,b,c,d,e,f,g}   Rodinò, Carmelina ^{a,b,c,d,e,f,g}   Soldani, Marcello ^{a,b,c,d,e,f,g}   Tonato, Maurizio ^{a,b,c,d,e,f,g}   Finardi, Cecilia ^{a,b,c,d,e,f,g}  

^a Medical Oncology Institutions   (Italy)

^b GOIRC Group   (Italy)

^c GOIRC Group   (Italy)

^d GOIRC Group   (Italy)

^e Medical Oncology Institutions   (Italy)

^f Medical Oncology Institutions   (Italy)

^g Medical Oncology Institutions   (Italy)

^h UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Chemotherapy; FAM; Gastric carcinoma; PAM

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SCREENING; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH CARCINOMA; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCINS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS;

EID: 0030064220     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960115)77:2<245::AID-CNCR4>3.0.CO;2-L     Document Type: Article

References (22)

1. Wills J, Bleiberg H. Current status of chemotherapy for gastric cancer. Eur J Cancer Clin Oncol 1989;25:3-8.
2. Beer M, Cocconi G, Ceci G, Varini M, Cavalli F. A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 1983 19;717-20.
3. Leichman L, Berry BT. Cisplatin therapy for adenocarcinoma of the stomach. Semin Oncol 1991;18:25-33.
4. Macdonald JS, Schein PS, Woolley PV, Smythe T, Veno W, Hoth D, et al. 5-Fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy in advanced gastric carcinoma. Ann Intern Med 1980;93:533-6.
5. Beretta G, Arnoldi E, Beretta GD. A randomized study of fluorouracil versus FAM polychemotherapy in gastric carcinoma. Proceedings of the EORTC symposium in "Advances in Gastrointestinal Tract Cancer Research and Treatment." 1989 Nov 17; Strasbourg, France[As tract No. 48].
6. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin. JAMA 1985; 253:2061-7.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
8. Kaplan EL, Meier P. Nonparametric estimation from incom-plete observations. J Am Stat Assoc 1958;53:457-81.
9. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977;35:1-39.
10. Moertel CG. Chemotherapy of gastrointestinal cancer. Clin Gastroenterol. 1976;5:777-93.
11. Moertel CG. Carcinoma of the stomach: prognostic factors and criteria of response to therapy. In: Staquet MJ, editor. Cancer therapy: prognostic factors and criteria of response. New York: Raven Press, 1975;229-36.
12. The Gastrointestinal Tumor Study Group. Randomized study of combination chemotherapy in unresectable gastric cancer. Cancer 1984;53:13-7.
13. De Lisi V, Cocconi G, Tonato, Di Costanzo F, Leonardi F, Soldani M. Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin and mitomycin (BAFMi) in the treatment of advanced gastric cancer. A phase III trial of the Italian Clinical Research Oncology Group (GOIRC). Cancer Treat Rep 1986;70:481-5.
14. Cocconi G, De Lisi V, Di Blasio B. Randomized comparison of 5-FU alone or combined with Mitomycin and Cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treat Rep 1982;66:1263-6.
15. De Vita V, Hellman S, Rosenberg SA. Cancer of the stomach. In: Cancer principles and practice of oncology. 4th Edition. Philadelphia: J.B. Lippincott Co., 1983;818-48.
16. Cocconi G. Chemotherapy of advanced gastric carcinoma: to be completely rewritten? Ann Oncol 1994;5:8-11.
17. Cullinan SA, Moertel CG, Wieand HS, O'Connel MJ, Poon MA, Krook JE, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. J Clin Oncol 1994;12:412-6.
18. PreusserP, Wilke H, Achterrath W, Fink U, Leiiaz A, Heinicke A, et al. Phase II study with the combination of etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-7.
19. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, et al. FAMTX versus etoposide, doxorubicin and cisplatin: a random assignment trial in gastric cancer. J Can Oncol 1992;10:541-8.
20. Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, et al. An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 1986;4:1799-803.
21. Cocconi G, Bella M, Zironi S, Algeri R, Di Costanzo F, De Lisi V, et al. Fluorouracil, Doxorubicin, and Mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1994;12:2687-93.
22. Wils J, Klein H, Wagener DJTh, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin. A step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 1991;9:827-31.